Tenax Therapeutics, Inc. (TENX) - Q2 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Tenax Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel formulations of levosimendan for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF) and imatinib for pulmonary arterial hypertension (PAH). The company is currently prioritizing its Phase 3 LEVEL trial for oral levosimendan and has suspended plans for an imatinib Phase 3 trial.
Key Financial Metrics
| Metric | Q2 2024 (3 Months) | YTD 2024 (6 Months) | YTD 2023 (6 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(3,575,673) | $(7,374,513) | $(2,513,098) |
| Operating Expenses | $3,672,021 | $7,580,347 | $2,775,624 |
| Cash and Cash Equivalents (End of Period) | $9,384,015 | $9,384,015 | $13,393,573 |
| Working Capital | $8,874,955 | $8,874,955 | $8,098,107 |
| Accumulated Deficit | $(304,627,266) | $(304,627,266) | $(292,055,178) |
| Debt (Note Payable) | $278,802 | $278,802 | $500,903 |
Note: The company has no revenue. Margins are not applicable due to zero revenue.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased by 173% year-over-year for the six months ended June 30, 2024 ($7.58M vs. $2.78M). This was driven primarily by a 979% increase in Research and Development (R&D) expenses ($5.0M vs. $0.46M), attributed to the initiation and enrollment of the Phase 3 LEVEL trial for oral levosimendan.
- Net Loss: Net loss for the six months ended June 30, 2024, was $7.37M, compared to $2.51M in the same period in 2023.
- Cash Flow: Net cash used in operating activities increased to $8.2M for the six months ended June 30, 2024, from $2.6M in the prior year period, reflecting higher clinical study costs.
- Capital Structure: The company completed a 1-for-80 reverse stock split on January 2, 2024. As of June 30, 2024, there were 1,958,245 shares of common stock outstanding.
Guidance, Outlook, and Subsequent Events
- Subsequent Financing: On August 8, 2024, the company closed a private placement financing generating gross proceeds of approximately $100 million. This includes the sale of common stock, pre-funded warrants, and accompanying warrants.
- Liquidity Outlook: Management states that the $100 million in proceeds, combined with existing cash balances, is sufficient to fund operations through the end of calendar year 2027. This financing has removed substantial doubt about the company's ability to continue as a going concern.
- Clinical Strategy: The company plans to use proceeds to complete the Phase 3 LEVEL trial and initiate a second Phase 3 trial of oral levosimendan in 2025. The imatinib Phase 3 trial remains suspended.
- Risks: The company faces risks related to clinical trial outcomes, regulatory approval timelines, and the need for future capital if development costs exceed current projections. There are no material pending legal proceedings.
Investor Verification Checklist
- Verify the final net proceeds from the August 2024 private placement after deducting placement agent fees and offering expenses.
- Confirm the enrollment rates and timeline for the Phase 3 LEVEL trial for oral levosimendan.
- Review the terms of the amended license agreement with Orion Corporation regarding royalty rates and milestone payments (up to $45M in commercial milestones).
- Monitor the dilution impact from the exercise of pre-funded warrants and warrants issued in the August 2024 financing.
- Assess the company's burn rate relative to the projected runway through 2027.